直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

At the PTAB Blog

PTAB Statistics for Final Written Decisions Issued in December 2024 and January 2025

February 28, 2025

Authored and Edited by Daniel F. Klodowski; Umber Aggarwal; Deena Kablaoui Lanier; Nicholas A. Eitsert; A. Sasha Hoyt; Elliot C. Cook

In December, the PTAB cancelled 370 (77.57%) instituted claims across 27 IPR and PGR Final Written Decisions, including decisions issued following remand from the Federal Circuit.  After review, 102 (21.38%) instituted claims survived, and patent owners conceded 5 (1.05%) instituted claims through motions to amend or disclaimer.  For comparison, the cumulative average cancellation rate of instituted claims in IPR, CBM, and PGR Final Written Decisions is about 74%.

On a per-case basis, no instituted or substitute claims survived in 15 (55.56%) decisions, all instituted claims survived in 7 (25.93%) decision, and 5 (18.52%) decisions had a mixed outcome in which at least one instituted or substitute claim survived and at least one instituted claim was cancelled.  

In January, a relatively favorable month for patent challengers, the PTAB cancelled 491 (80.49%) instituted claims across 33 IPR and PGR Final Written Decisions. In those decisions, 117 (19.18%) instituted claims survived, and patent owners conceded 2 (0.33%) instituted claims through motions to amend or disclaimer.

On a per-case basis, no instituted or substitute claims survived in 19 (57.58%) decisions, all instituted claims survived in 3 (9.09%) decisions, and a mixed outcome occurred in 11 (33.33%) decisions in January.

Turning to motions to amend that were addressed on the merits in a Final Written Decision, the PTAB has cumulatively granted 662 (15.61%) proposed substitute claims while denying 3,580 (84.39%) proposed substitute claims through January 31, 2025. 

Patentees have had slightly more success with motions to amend in PGRs.  Through January 31, 2025, the PTAB granted 69 (20.60%) proposed substitute claims in PGR motions to amend while denying 266 (79.40%) proposed substitute claims.

The overall cumulative instituted claim survival rate in IPRs, CBMs, and PGRs through January 31, 2025, broken down by technology center, is as follows:

The cumulative number of Final Written Decisions through January 31, 2025, separated by technology center, is as follows:

Additional cumulative statistics on the Board’s IPR, CBM, and PGR decisions, updated through January 31, 2025, are available here on the At the PTAB blog.

Related Practices

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Offices

Reston, VA

Washington, DC

Contacts

Daniel F. Klodowski
Partner
Washington, DC
+1 202 408 4216
Email
Umber Aggarwal
Associate
Reston, VA
+1 571 203 2423
Email
Deena Kablaoui Lanier
Associate
Washington, DC
+1 202 408 4115
Email
Nicholas A. Eitsert
Associate
Washington, DC
+1 202 408 4157
Email
A. Sasha Hoyt
Associate
Washington, DC
+1 202 408 4000
Email
Elliot C. Cook
Partner
Reston, VA
+1 571 203 2738
Email

Copyright © 2025 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Panel Discussion

2026 Advanced Patent Law Institute

December 3-4, 2026

Stanford

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Seminar

The Augmented Practice 2026: Balancing AI Opportunity, Governance, and Risk

November 5, 2026

San Francisco

Conference

2026 TIPA International Symposium

October 30, 2026

Taipei City

Conference

4th Global Patent Litigation FORUM

October 29, 2026

Munich

Hybrid Conference

2026 Patent Law Institute: Critical Issues & Best Practices – New York

October 29, 2026

New York

Hybrid Conference

Intellectual Property Law Institute 2026 – California

October 19-20, 2026

San Francisco

Hybrid Seminar

Annual Intellectual Property Law Section Fall Seminar

October 16, 2026

Alexandria

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP